Wouter W De Herder

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7881406/publications.pdf

Version: 2024-02-01

213 papers	14,536 citations	26630 56 h-index	20358 116 g-index

220 all docs	220 docs citations	220 times ranked	9974 citing authors

#	Article	IF	Citations
1	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13040.	2.6	12
2	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13044.	2.6	14
3	ENETS standardized (synoptic) reporting in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13054.	2.6	7
4	Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1969-e1975.	3.6	11
5	The Surprising Irish Giant of St. Jamesâ€™s Street by Thomas Rowlandson. The acromegalic giant Patrick Cotter (1760â€“1806). Journal of Endocrinological Investigation, 2022, , 1.	3.3	2
6	Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the Netherlands. Endoscopy International Open, 2022, 10, E940-E951.	1.8	3
7	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. Journal of Neuroendocrinology, 2022, 34, e13105.	2.6	12
8	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology, 2022, 33, 115-154.	9.0	227
9	Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3203-3214.	6.4	8
10	Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases. Endocrine-Related Cancer, 2022, 29, 241-250.	3.1	3
11	Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus. European Journal of Endocrinology, 2022, 186, 597-605.	3.7	2
12	Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients. European Journal of Endocrinology, 2022, , .	3.7	1
13	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3313-e3320.	3.6	7
14	Multidisciplinary integrated care pathway for von Hippelâ€“Lindau disease. Cancer, 2022, , .	4.1	7
15	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Annals of Surgical Oncology, 2022, 29, 5568-5577.	1.5	4
16	Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. European Journal of Cancer Care, 2022, 31, .	1.5	3
17	Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. European Journal of Endocrinology, 2022, , .	3.7	4
18	Health-Related Quality of Life in Patients with Multiple Endocrine Neoplasia Type 1. Neuroendocrinology, 2021, 111, 288-296.	2.5	15

#	Article	IF	Citations
19	Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?. Neuroendocrinology, 2021, 111, 170-177.	2.5	8
20	The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1014-e1027.	3.6	14
21	Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours. Cancers, 2021, 13, 443.	3.7	12
22	Should everolimus be stopped after radiological progression in metastatic insulinoma? A â€œproâ€•point of view. Endocrine, 2021, 71, 256-257.	2.3	2
23	Neuroendocrine Neoplasms (NENs) in Complex Genetic Disorders. Endocrinology, 2021, , 361-373.	0.1	0
24	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	2.8	12
25	Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Current Oncology Reports, 2021, 23, 46.	4.0	8
26	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2021, 27, 2989-2995.	7.0	42
27	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. Annals of Oncology, 2021, 32, 439-451.	1.2	101
28	INTENSIVE: InterNaTional rEgistry oN Sars-cov-2 posItiVe nEuroendocrine neoplasm patients.. Journal of Clinical Oncology, 2021, 39, e16205-e16205.	1.6	0
29	Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	3
30	Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3665-e3672.	3.6	23
31	Medical treatment of neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 139-144.	1.4	0
32	Aldo Molinari: the wedding of the giant Almiro Crema in Torino. Journal of Endocrinological Investigation, 2021, , 1.	3.3	1
33	A circus postcard showing short statue in a clown and a horse. Journal of Endocrinological Investigation, 2021, , 1.	3.3	0
34	Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3515-3525.	3.6	5
35	Predicting symptomatic mesenteric mass in small intestinal neuroendocrine tumors using radiomics. Endocrine-Related Cancer, 2021, 28, 529-539.	3.1	4
36	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	11.4	34

#	Article	IF	Citations
37	The possibilities and impossibilities of treating acromegaly 50 years ago illustrated by Diane Arbus, A Jewish Giant at Home with his Parents, 1970. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	0
38	The acromegalic? Giant Samuel MacDonald and the short stature George Cranstoun by John Kay. Journal of Endocrinological Investigation, 2021, , 1.	3.3	2
39	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer, Supplement, 2021, 16, 5-13.	2.2	2
40	The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 407-417.	3.6	13
41	Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocrine Reviews, 2020, 41, 371-403.	20.1	116
42	Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells. Neuroendocrinology, 2020, 110, 351-363.	2.5	14
43	ClÃ©mentine Delait (1865â€“1934), the most famous bearded lady on the continent in the 20th century. Gynecological Endocrinology, 2020, 36, 213-217.	1.7	0
44	Toni Mochty: Bardet Biedl syndrome â€œavant la lettreâ€• Clinical Genetics, 2020, 97, 536-537.	2.0	0
45	A placeboâ€controlled proofâ€ofâ€concept study of alirocumab on postprandial lipids and vascular elasticity in insulinâ€treated patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2020, 22, 807-816.	4.4	12
46	Hereditary acromegalic gigantism in the family of Roman Emperor Maximinus Thrax. Medical Hypotheses, 2020, 136, 109525.	1.5	2
47	From dwarves to giants: South American's contribution to the history of growth hormone and related disorders. Growth Hormone and IGF Research, 2020, 50, 48-56.	1.1	4
48	Clues For Genetic Anticipation In Multiple Endocrine Neoplasia Type 1. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2491-e2500.	3.6	7
49	Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 561-570.	10.7	48
50	Outcomes after Tricuspid Valve Replacement for Carcinoid Heart Disease: A Multicenter Study. Structural Heart, 2020, 4, 122-130.	0.6	1
51	Importance of Complete Pathology Reporting for Neuroendocrine Carcinoma: WHO Guidelines Are a Good Start but Not Enough. Neuroendocrinology, 2020, 110, 994-1000.	2.5	4
52	The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study. Endocrine, 2020, 68, 640-649.	2.3	4
53	Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocrine-Related Cancer, 2020, 27, R391-R405.	3.1	14
54	Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. Endocrine-Related Cancer, 2020, 27, 615-624.	3.1	15

#	Article	IF	Citations
55	Editorial: Early Genetic and Clinical Diagnosis in MEN1. Frontiers in Endocrinology, 2020, 11, 218.	3.5	0
56	Insulinoma. , 2019, , 58-62.		0
57	Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 2019, 26, 1-12.	3.1	24
58	Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG). Journal of Surgical Oncology, 2019, 120, 966-975.	1.7	20
59	Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their â€œLetter to the Editorâ€• Neuroendocrinology, 2019, 108, 366-366.	2.5	0
60	Letter to the Editor: â€œThe Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Studyâ€• Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5104-5105.	3.6	1
61	Turning Up the Heat: Endoscopic Ablation of Pancreatic Neuroendocrine Neoplasms. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5053-5055.	3.6	2
62	Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. Hormones and Cancer, 2019, 10, 107-119.	4.9	10
63	Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1336-1344.	3.6	95
64	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. Endocrine, 2019, 64, 673-684.	2.3	23
65	Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. BMC Cancer, 2019, 19, 325.	2.6	38
66	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs, 2019, 79, 21-42.	10.9	54
67	Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group. Neuroendocrinology, 2019, 108, 5-6.	2.5	8
68	Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 704-717.	6.4	90
69	Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. European Journal of Endocrinology, 2019, 181, 45-53.	3.7	63
70	Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer, 2019, 26, R157-R179.	3.1	34
71	Management of carcinoid syndrome: a systematic review and meta-analysis. Endocrine-Related Cancer, 2019, 26, R145-R156.	3.1	59
72	MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. Endocrine-Related Cancer, 2019, 26, 367-378.	3.1	16

#	Article	IF	Citations
73	Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 585-599.	3.1	16
74	Neuroendocrine Neoplasms (NENs) in Complex Genetic Disorders. Endocrinology, 2019, , 1-13.	0.1	0
75	MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1027-1032.	7.1	88
76	Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocrine-Related Cancer, 2018, 25, 245-254.	3.1	35
77	The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology, 2018, 106, 357-365.	2.5	57
78	Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocrine-Related Cancer, 2018, 25, R115-R130.	3.1	41
79	Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocrine-Related Cancer, 2018, 25, L37-L42.	3.1	57
80	Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm. Annals of Surgery, 2018, 267, 1155-1160.	4.2	51
81	Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 46-55.	3.6	19
82	Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors. Journal of Endocrinological Investigation, 2018, 41, 655-661.	3.3	11
83	Melena in a Patient With a Metastasized Neuroendocrine Tumor. Gastroenterology, 2018, 154, e6-e7.	1.3	0
84	Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2018, 59, 452-458.	5.0	88
85	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. Neuroendocrinology, 2018, 107, 375-386.	2.5	78
86	Role of biomarker tests for diagnosis of neuroendocrine tumours. Nature Reviews Endocrinology, 2018, 14, 656-669.	9.6	84
87	Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterology, 2018, 18, 84.	2.0	32
88	When and How to Use Somatostatin Analogues. Endocrinology and Metabolism Clinics of North America, 2018, 47, 549-555.	3.2	10
89	Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study. Neuroendocrinology, 2018, 107, 315-323.	2.5	10
90	DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment. European Journal of Endocrinology, 2018, 179, 153-160.	3.7	26

#	Article	IF	Citations
91	High Fear of Disease Occurrence Is Associated With Low Quality of Life in Patients With Multiple Endocrine Neoplasia Type 1: Results From the Dutch MEN1 Study Group. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2354-2361.	3.6	29
92	Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.5	12
93	Role of the tumor microenvironment in digestive neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, R519-R544.	3.1	13
94	Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget, 2018, 9, 14791-14802.	1.8	50
95	Erythrocyteâ€bound apolipoprotein B in atherosclerosis and mortality. European Journal of Clinical Investigation, 2017, 47, 289-296.	3.4	3
96	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology, 2017, 105, 245-254.	2.5	122
97	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors. Neuroendocrinology, 2017, 105, 193-195.	2.5	37
98	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clinical Cancer Research, 2017, 23, 4617-4624.	7.0	399
99	Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocrine-Related Cancer, 2017, 24, R261-R274.	3.1	43
100	Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease. Clinical Pharmacology and Therapeutics, 2017, 102, 1017-1024.	4.7	12
101	Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clinical Endocrinology, 2017, 87, 165-170.	2.4	21
102	MEN1-Dependent Breast Cancer: Indication for Early Screening? Results From the Dutch MEN1 Study Group. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2083-2090.	3.6	49
103	Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?. Lancet Oncology, The, 2017, 18, e299.	10.7	4
104	Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Endocrine-Related Cancer, 2017, 24, 243-251.	3.1	45
105	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 2017, 28, 1309-1315.	1.2	82
106	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. Neuroendocrinology, 2017, 105, 281-294.	2.5	94
107	ENDOCRINOLOGY IN PREGNANCY: Pheochromocytoma in pregnancy: case series and review of literature. European Journal of Endocrinology, 2017, 177, R49-R58.	3.7	48
108	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology, 2017, 105, 266-280.	2.5	122

#	Article	IF	Citations
109	Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework. Annals of Oncology, 2017, 28, 3022-3027.	1.2	15
110	Oldest case of gigantism? Assessment of the alleged remains of Sa-Nakht, king of ancient Egypt. Lancet Diabetes and Endocrinology,the, 2017, 5, 580-581.	11.4	8
111	Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1â€"Results From the Dutch MEN1 Study Group. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3795-3805.	3.6	60
112	Adrenal Cushingâ€™s syndrome during pregnancy. European Journal of Endocrinology, 2017, 177, K13-K20.	3.7	32
113	Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group. Pancreatology, 2017, 17, 766-772.	1.1	26
114	The need for national registries for rare endocrine tumor syndromes. Endocrine, 2017, 58, 205-206.	2.3	0
115	Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. Neuroendocrinology, 2017, 105, 394-402.	2.5	27
116	Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushingâ€™s syndrome. JCI Insight, 2017, 2, .	5.0	38
117	Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2922-2929.	3.6	15
118	Leucocyteâ€bound apolipoprotein B in the circulation is inversely associated with the presence of clinical and subclinical atherosclerosis. European Journal of Clinical Investigation, 2016, 46, 690-697.	3.4	3
119	Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?. Endocrine Connections, 2016, 5, 143-151.	1.9	4
120	Effect of a single dose vitamin D3 on postprandial arterial stiffness and inflammation in vitamin D deficient women. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3394.	3.6	10
121	MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Medicine, 2016, 14, 182.	5.5	95
122	Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4574-4584.	3.6	18
123	Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells. Neuroendocrinology, 2016, 103, 815-825.	2.5	11
124	Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. European Journal of Endocrinology, 2016, 175, 361-366.	3.7	42
125	Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. Endocrine-Related Cancer, 2016, 23, 727-737.	3.1	21
126	Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?. Neuroendocrinology, 2016, 103, 560-566.	2.5	30

#	Article	IF	Citations
127	Saint Wilgefortis: sudden hirsutism to prevent an unwanted marriage. Journal of Endocrinological Investigation, 2016, 39, 1475-1475.	3.3	2
128	Potential value of EUS in pancreatic surveillance of VHL patients. European Journal of Endocrinology, 2016, 174, 611-620.	3.7	10
129	The History of Acromegaly. Neuroendocrinology, 2016, 103, 7-17.	2.5	45
130	Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells. Endocrine, 2016, 52, 664-667.	2.3	8
131	A short history of neuroendocrine tumours and their peptide hormones. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 3-17.	4.7	39
132	Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 103-114.	4.7	54
133	Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. British Journal of Cancer, 2016, 114, 650-658.	6.4	69
134	Pareidolia in Neuroendocrinology: A Pituitary Macroadenoma Resembling â€œBig Birdâ€• Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1348-1349.	3.6	2
135	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology, 2016, 103, 139-143.	2.5	241
136	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 2016, 103, 119-124.	2.5	380
137	Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1159-1165.	3.6	41
138	Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. European Journal of Endocrinology, 2016, 174, 271-280.	3.7	65
139	Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Annals of Oncology, 2016, 27, 746-747.	1.2	30
140	Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 453-463.	6.4	125
141	Selenium Status Is Positively Associated with Bone Mineral Density in Healthy Aging European Men. PLoS ONE, 2016, 11, e0152748.	2.5	48
142	Operative Treatment of Primary Hyperparathyroidism in Daycare Surgery. Scandinavian Journal of Surgery, 2015, 104, 196-199.	2.6	8
143	Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. Journal of Molecular Endocrinology, 2015, 54, 137-147.	2.5	83
144	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocrine-Related Cancer, 2015, 22, 745-757.	3.1	155

#	Article	IF	Citations
145	Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1. European Journal of Endocrinology, 2015, 172, 337-342.	3.7	10
146	X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocrine-Related Cancer, 2015, 22, 353-367.	3.1	151
147	Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncology, The, 2015, 16, e435-e446.	10.7	217
148	Energy and metabolic alterations in predisposition to pheochromocytomas and paragangliomas: the so-called Warburg (and more) effect, 15 years on. Endocrine-Related Cancer, 2015, 22, E5-E7.	3.1	2
149	Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3288-3296.	3.6	116
150	Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate. Journal of Nuclear Medicine, 2015, 56, 1647-1653.	5.0	97
151	No Association of Blood Type O With Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3850-3855.	3.6	6
152	EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointestinal Endoscopy, 2015, 81, 159-167.e2.	1.0	69
153	Pituitary hyperplasia: an uncommon presentation of a common disease. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150056.	0.5	7
154	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocrine-Related Cancer, 2014, 21, 601-613.	3.1	25
155	Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis, Management, and Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3060-3069.	3.6	56
156	Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome. Neoplasia, 2014, 16, 868-873.	5.3	55
157	Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocrine-Related Cancer, 2014, 21, R153-R163.	3.1	238
158	Heroes in endocrinology: Nobel Prizes. Endocrine Connections, 2014, 3, R94-R104.	1.9	31
159	GEP-NETs update: Functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). European Journal of Endocrinology, 2014, 170, R173-R183.	3.7	24
160	Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. Endocrine-Related Cancer, 2014, 21, 653-661.	3.1	39
161	Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation. PLoS ONE, 2014, 9, e104944.	2.5	10
162	Low Accuracy of Tumor Markers for Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4143-4151.	3.6	74

#	Article	IF	Citations
163	Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. Neurology, 2012, 79, 793-796.	1.1	57
164	Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer, 2012, 19, 657-666.	3.1	169
165	New developments in the medical treatment of Cushing's syndrome. Endocrine-Related Cancer, 2012, 19, R205-R223.	3.1	38
166	Acromegalic gigantism, physicians and body snatching. Past or present?. Pituitary, 2012, 15, 312-318.	2.9	6
167	5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. Bone, 2012, 50, 1260-1265.	2.9	13
168	Familial gigantism. Clinics, 2012, 67, 29-32.	1.5	7
169	P51. Pregnancy stimulates cerebellar hemangioblastoma growth in von Hippel-Lindau disease. Pregnancy Hypertension, 2011, 1, 297.	1.4	0
170	New therapeutic options for metastatic malignant insulinomas. Clinical Endocrinology, 2011, 75, 277-284.	2.4	54
171	Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3381-3389.	3.6	78
172	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	3.6	323
173	NANETS Treatment Guidelines. Pancreas, 2010, 39, 735-752.	1.1	494
174	Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocrine-Related Cancer, 2010, 17, R173-R193.	3.1	89
175	ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. Neuroendocrinology, 2009, 90, 159-161.	2.5	20
176	Effects of Somatostatin Analogs on a Growth Hormone-Releasing Hormone Secreting Bronchial Carcinoid,in Vivoandin VitroStudies. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 428-433.	3.6	41
177	Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1118-1124.	3.6	109
178	Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). Pituitary, 2009, 12, 236-244.	2.9	44
179	4 Movie Actors with Acromegaly/Gigantism. Journal of Endocrinological Investigation, 2009, 32, 791-792.	3.3	1
180	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 749-755.	6.4	104

#	Article	IF	Citations
181	Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology, The, 2008, 9, 61-72.	10.7	1,474
182	Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4598-4601.	3.6	146
183	Biochemistry of neuroendocrine tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 33-41.	4.7	112
184	Somatostatin receptor imaging for neuroendocrine tumors. Pituitary, 2006, 9, 243-248.	2.9	69
185	TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 395-401.	2.8	1,403
186	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. Neuroendocrinology, 2006, 84, 183-188.	2.5	248
187	Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?. European Journal of Endocrinology, 2006, 155, 717-723.	3.7	20
188	Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 705-715.	2.4	39
189	The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clinical Endocrinology, 2005, 63, 176-184.	2.4	59
190	Somatostatin Analogs as Radiodiagnostic Tools. Reviews in Endocrine and Metabolic Disorders, 2005, 6, 23-27.	5.7	6
191	Carcinoid syndrome: diagnosis and medical management. Arquivos Brasileiros De Endocrinologia E Metabologia, 2005, 49, 850-860.	1.3	56
192	Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. European Journal of Endocrinology, 2005, 153, 67-71.	3.7	42
193	Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. Journal of Clinical Oncology, 2005, 23, 2754-2762.	1.6	602
194	Endocrinology and Art. Journal of Endocrinological Investigation, 2005, 28, 392-392.	3.3	5
195	Neuroendocrine tumors and somatostatin: imaging techniques. Journal of Endocrinological Investigation, 2005, 28, 132-6.	3.3	33
196	The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomasin Vitro. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1577-1585.	3.6	178
197	Insulinoma. Neuroendocrinology, 2004, 80, 20-22.	2.5	28
198	Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide. Neuroendocrinology, 2004, 80, 244-251.	2.5	152

#	Article	IF	Citations
199	A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 638-645.	3.6	138
200	Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas.. Endocrine-Related Cancer, 2004, 11, 19-34.	3.1	35
201	Cerebrospinal Fluid Leakage During Transsphenoidal Surgery: Postoperative External Lumbar Drainage Reduces the Risk for Meningitis. Pituitary, 2004, 7, 89-93.	2.9	66
202	Gut endocrine tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2004, 18, 477-495.	4.7	22
203	Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors. Endocrine, 2003, 20, 285-290.	2.2	30
204	Addisonian crisis and relative adrenal failure. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 143-147.	5.7	74
205	Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.. Endocrine-Related Cancer, 2003, 10, 451-458.	3.1	189
206	Somatostatin Receptors in Pheochromocytoma. , 2003, 31, 145-154.		11
207	Carcinoid crisis during transesophageal echocardiography. Intensive Care Medicine, 2000, 26, 254-254.	8.2	21
208	Risk Factors for Meningitis After Transsphenoidal Surgery. Clinical Infectious Diseases, 1997, 25, 852-856.	5.8	69
209	Octreotide. New England Journal of Medicine, 1996, 334, 246-254.	27.0	1,077
210	Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of lodothyronines and other substrates in rats. Endocrine, 1996, 4, 79-85.	2.3	12
211	Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. FEBS Letters, 1993, 324, 358-360.	2.8	59
212	On the enterohepatic cycle of triiodothyronine in rats; importance of the intestinal microflora. Life Sciences, 1989, 45, 849-856.	4.3	29
213	Neuroendocrine Tumors. , 0, , 564-668.		0